The DOI matches its Crossref record; 53 of the 54 references it cites were found in a registry or an index.
CHEK2 knockout is a therapeutic target for TP53-mutated hepatocellular carcinoma
Open accessAbstract
Currently, there is still a lack of novel and effective drug targets to improve the prognosis of hepatocellular carcinoma (HCC). Additionally, the role of CHEK2 in HCC has not been reported yet. The eQTLgen database and two HCC Genome-Wide Association Study (GWAS) datasets (ieu-b-4953, ICD10 C22.0) were used to find the drug target: CHEK2. Next, Colony, Edu, β-gal, and cell cycle analysis were facilitated to evaluate the role of CHEK2 knockout in HCC. In addition, Nultin-3 was added to evaluate the apoptosis of TP53-mutated HCC cells with CHEK2 knockout. Furthermore, MitoSox, electron microscopy, mitochondrial ATP, and NADH+/NADH levels were assessed in the CHEK2 knockout HCC cells with or without Metformin. Finally, cell-derived tumor xenograft was used to evaluate the role of CHEK2 knockout in vivo. We initially identified a potential drug target, CHEK2, through GWAS data analysis. Furthermore, we observed a significant upregulation of CHEK2 expression in HCC, which was found to be correlated with a poor prognosis. Subsequently, the results indicated that knocking out CHEK2 selectively affects the proliferation, cell cycle, senescence, and apoptosis of TP53-mutant HCC cells. Additionally, the introduction of Nultin-3 further intensified the functional impact on TP53-mutant cells. Then ClusterProfiler results showed high CHEK2 and TP53 mutation group was positively enriched in the mitochondrial ATP pathway. Then we used MitoSox, electron microscopy, mitochondrial ATP, and NADH + /NADH assay and found knockout of CHECK could induce the ATP pathway to inhibit the growth of HCC. Our research introduces a novel drug target for TP53-mutant HCC cells via mitochondrial ATP, addressing the limitation of Nultin-3 as a standalone treatment that does not induce tumor cell death.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The confluence of mutagenic stress and impaired detoxification triggers oncogene activation and tumor-suppressor silencing, culminating in the malignant evolution to HCC [117].”
From Constructing biomimetic microenvironments for liver regeneration (2025) · doi:10.1186/s12951-025-03729-9 · cites this paper as [117]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
KEGG: Kyoto Encyclopedia of Genes and Genomes
Kanehisa, M. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.1.27 · Cited by 37,077
KEGG: Kyoto Encyclopedia of Genes and Genomes
Ogata, H., Goto, S., Sato, K., Fujibuchi, W., Bono, H., & Kanehisa, M. (1999) · Nucleic Acids Research · doi:10.1093/nar/27.1.29 · Cited by 31,232 · cited 1×
“Cloned sgRNA sequences used are as follows: sgCHEK2 1# : AAGGGCCCATAATC GAGCCC; sgCHEK2 2# : CTGCCCCCTGGGCTCGATTA.”
MethodHallmarks of Cancer: New Dimensions
Hanahan, D. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1059 · Cited by 9,887 · cited 1×
“Cloned sgRNA sequences used are as follows: sgCHEK2 1# : AAGGGCCCATAATC GAGCCC; sgCHEK2 2# : CTGCCCCCTGGGCTCGATTA.”
MethodThe Reactome pathway Knowledgebase
Fabregat, A., Sidiropoulos, K., Garapati, P., Gillespie, M., Hausmann, K., Haw, R., Jassal, B., Jupe, S., Korninger, F., McKay, S., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1351 · Cited by 5,605
Mermel, C. H., Schumacher, S. E., Hill, B., Meyerson, M. L., Beroukhim, R., & Getz, G. (2011) · Genome Biology · doi:10.1186/gb-2011-12-4-r41 · Cited by 3,550
Review The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge
Tomczak, K., Czerwińska, P., & Wiznerowicz, M. (2015) · Współczesna Onkologia · doi:10.5114/wo.2014.47136 · Cited by 3,492 · cited 1×
“For each HCC patient, an HCC specimen, a matched normal specimen, and a fresh plasma sample before surgery were collected and analyzed.”
MethodFerroptosis as a p53-mediated activity during tumour suppression
Jiang, L., Kon, N., Li, T., Wang, S.-J., Su, T., Hibshoosh, H., Baer, R., & Gu, W. (2015) · Nature · doi:10.1038/nature14344 · Cited by 3,398 · cited 13×
“Moreover, for investigating the clinical indices of CHEK2 in HCC, we selected TCGA, ICGC, and GAO et al. cohorts and we found higher CHEK2 group predicted poor overall survival rates than the lower CHEK2 group (Fig.”
BackgroundMethodInfluentialIntegration of summary data from GWAS and eQTL studies predicts complex trait gene targets
Zhu, Z., Zhang, F., Hu, H., Bakshi, A., Robinson, M. R., Powell, J. E., Montgomery, G. W., Goddard, M. E., Wray, N. R., Visscher, P. M., et al. (2016) · Nature Genetics · doi:10.1038/ng.3538 · Cited by 3,352 · cited 1×
“…Genome Consortium (ICGC), GAO et al cohorts [41, 42], as well as 22 Gene Expression Omnibus database (GEO) datasets (GSE5364, GSE6222, GSE6764, GSE14323, GSE14520, GSE19665, GSE25097, GSE25599, GSE36376, GSE45436, GSE55092, GSE62232, GSE77314, GSE84402, GSE89377, GSE64990, GSE101685, GSE101728,…”
Self-citationMendelian Randomization as an Approach to Assess Causality Using Observational Data
Sekula, P., Del Greco M, F., Pattaro, C., & Köttgen, A. (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016010098 · Cited by 2,351 · cited 1×
“In MR studies, confounding bias can be minimized since genetic variations are inherently randomized at birth, ensuring that they are not in fl uenced by external factors and reducing the possibility of reverse causation as genetic variants are determined before disease development [5].”
Background
Cited by
Wang, Z., Lin, X., Shi, Y., Yan, H., Shang, Y., & Ren, H. (2026) · Biomedical Technology · doi:10.1016/j.bmt.2025.100131 · Cited by 22
Self-citationConstructing biomimetic microenvironments for liver regeneration
(2025) · doi:10.1186/s12951-025-03729-9 · Cited by 11
“The confluence of mutagenic stress and impaired detoxification triggers oncogene activation and tumor-suppressor silencing, culminating in the malignant evolution to HCC [117].”
Self-citationCharacterization of a pleomorphic rhabdomyosarcoma cell line
Stickler, S., Lang, C., Rieche, M., Eggerstorfer, M.-T., HOHENEGGER, M., Hochmair, M. J., & Hamilton, G. (2025) · Scientific Reports · doi:10.1038/s41598-025-87027-2 · Cited by 3
Shafee Ur Rehman, S. K. (2025) · International Journal of Biosciences (IJB) · doi:10.12692/ijb/27.1.142-155 · Cited by 1
Driver-associated transcriptional rewiring reveals conditional genetic vulnerabilities in cancerPreprint
Geraghty, S., Boyer, J. A., Fazel-Zarandi, M., Arzouni, N., Ryseck, R.-P., McBride, M. J., Parsons, L. R., Rabinowitz, J. D., & Singh, M. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.11.20.624509
Metadata
- Authors
- Chen, Y., Zhu, Z., Wu, X., Li, H., Guan, W., & Ren, H.
- Affiliations
- Nanjing Drum Tower Hospital (CN)
- Corresponding author
- Li, Hui
- Guan, Wenxian
- Ren, Haozhen
- Venue
- Cell Death Discovery
- Published
- 2024-01-19
- Volume
- 10
- Issue
- 1
- Pages
- 37-37
- ISSN
- 2058-7716 (ISSN-L)
- PMC
- PMC10799024
- OpenAlex
- W4391022989
- Cited by
- 6
- References
- 54
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 1
- FWCI
- 1.03
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Cell Death Discovery (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Natural Science Foundation of China (82270646)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Keywords
- CHEK2, hepatocellular carcinoma, TP53 mutation, therapeutic target, apoptosis, cellular senescence, cell cycle, metformin, tumor xenografts, prognosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CHEK2 knockout is a therapeutic target for TP53-mutated hepatocellular carcinoma. https://app.cochat.ai/papers/10.1038/s41420-023-01777-4
- The paper
- Chen, Y., Zhu, Z., Wu, X., Li, H., Guan, W., & Ren, H. (2024). CHEK2 knockout is a therapeutic target for TP53-mutated hepatocellular carcinoma. Cell Death Discovery. https://doi.org/10.1038/s41420-023-01777-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.